

PTO/SB/08A

OCT 02 2003

**FIFTH SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/606,027
Filing Date	June 25, 2003
Confirmation Number	To Be Assigned
First Named Inventor	Robert A. Holton
Group Art Unit	1625
Examiner Name	Ba K. Trinh
Sheet 1 of 5	Attorney Docket No. FSUM 10466.59

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
BT	1.	4,960,790		Stella et al.	10-02-1990
BT	2.	5,175,315		Holton	12-29-1992
BT	3.	5,200,534		Rao	04-06-1993
BT	4.	5,227,400		Holton et al.	07-13-1993
BT	5.	5,243,045		Holton et al.	09-07-1993
BT	6.	5,248,796		Chen et al.	09-28-1993
BT	7.	5,283,253		Holton et al.	02-01-1994
BT	8.	5,319,112		Kingston et al.	06-07-1994
BT	9.	5,350,866		Holton et al.	09-27-1994
BT	10.	5,352,806		Gunawardana et al.	10-04-1994
BT	11.	5,415,869		Straubinger et al.	05-16-1995
BT	12.	5,422,364		Nicolaou et al.	06-06-1995
BT	13.	5,430,160		Holton	07-04-1995
BT	14.	5,489,601		Holton et al.	02-06-1996
BT	15.	5,530,020		Gunawardana et al.	06-25-1996
BT	16.	5,567,614		Patel et al.	10-22-1996

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**FIFTH SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/606,027
Filing Date	June 25, 2003
Confirmation Number	To Be Assigned
First Named Inventor	Robert A. Holton
Group Art Unit	1625
Examiner Name	Ba K. Trinh
Attorney Docket No.	FSUM 10466.59

Sheet

2

of

5

17.	5,614,645	Kingston et al.	03-25-1997
18.	5,714,513	Holton et al.	02-03-1998
19.	5,721,268	Holton et al.	02-24-1998
20.	5,767,297	Mandai et al.	06-16-1998
21.	5,780,653	Tao et al.	07-14-1998
22.	5,811,452	Ojima et al.	09-22-1998
23.	5,879,929	Patel	03-09-1999
24.	5,912,264	Wittman et al.	06-15-1999
25.	5,965,739	Kelly et al.	10-12-1999
26.	6,136,988	Murray et al.	10-24-2000
27.	US 2001/0002404 A1	Webb et al.	05-31-2001

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
BT	28.	EP	0 590 267	A2	Bristol-Myers Squibb Co.	04-06-1994	
BT	29.	EP	0 629 701	B1	Bristol-Myers Squibb Co.	12-21-1994	
BT	30.	EP	0 558 959	B1	Bristol-Myers Squibb Co.	09-08-1993	
BT	31.	EP	0 747 385	B1	Bristol-Myers Squibb Co.	08-14-2002	
BT	32.	WO	90/10443	A1	University of Kansas	09-20-1990	

Examiner
SignatureDate
Considered


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A		C mplet if Known		
FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/606,027	
		Filing Date	June 25, 2003	
		Confirmation Number	To Be Assigned	
		First Named Inventor	Robert A. Holton	
		Group Art Unit	1625	
		Examiner Name	Ba K. Trinh	
Sheet	3	5	Attorney Docket No.	FSUM 10466.59


33.	WO	93/02065	A1	Rhone Poulenc Rorer	02-04-1993
34.	WO	94/14787	A1	Bristol-Myers Squibb Co.	07-07-1994
35.	WO	95/11241	A1	Rhone-Poulenc Rorer, S.A.	04-27-1995
36.	WO	95/13053	A1	The Research Foundation of State University of New York	05-18-1995
37.	WO	97/09979	A1	Florida State University	03-20-1997
38.	WO	97/42181	A1	Florida State University	11-13-1997
39.	WO	97/44026	A1	Neuromedica, Inc.	11-27-1997
40.	WO	97/44063	A2	Neuromedica, Inc.	11-27-1997
41.	WO	99/09021	A1	Florida State University	02-25-1999
42.	WO	00/01366	A1	Neopharm	01-13-2000
43.	WO	00/78707	A1	Napro Biotherapeutics, Inc.	12-28-2000
44.	WO	01/25223	A1	The Research Foundation of State University of New York	04-12-2001
45.	WO	01/57013	A1	Florida State University Research Foundation, Inc.	08-09-2001
46.	WO	01/57027	A1	Florida State University Research Foundation, Inc.	08-09-2001
47.	WO	01/68089	A1	Indena SPA	09-20-2001

Examiner Signature		Date Considered	12.03
--------------------	---	-----------------	-------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A					Compleat if Known	
FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number		10/606,027	
			Filing Date		June 25, 2003	
			Confirmation Number		To Be Assigned	
			First Named Inventor		Robert A. Holton	
			Group Art Unit		1625	
			Examiner Name		Ba K. Trinh	
Sheet	4	of	5	Attorney Docket No.		FSUM 10466.59

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
OF	48.	DEUTSCH et al. "Synthesis of Congeners and Prodrugs. 3. Water-Soluble Prodrugs of Taxol with Potent Antitumor Activity" Journal of Medicinal Chemistry, Vol. 32, No. 4 (1989) pp. 788-792.		
OF	49.	DUBOIS et al. "Fluorescent and Biotinylated Analogues of Docetaxel: Synthesis and Biological Evaluation" Bioorganic & Medicinal Chemistry, Vol. 3, No. 10 (1995) pp. 1357-1368.		
OF	50.	European Search Report for EP 01 10 2160 dated July 9, 2001.		
OF	51.	FERLINI et al. "Antitumor Activity of Novel Taxanes that Act at the Same Time as Cytotoxic Agents and P-Glycoprotein Inhibitors" British Journal of Cancer, Vol. 83, No. 12 (2000) pp. 1762-1768.		
OF	52.	GUENARD et al. "Effects of the Hydrophobicity of Taxoids on their Interaction with Tubulin" Bioorganic & Medicinal Chemistry, Vol. 8 (2000) pp. 145-156.		
OF	53.	GUERITTE-VOEGELEIN et al. "Relationships between the Structure of Taxol Analogues and Their Antimitotic Activity" Journal of Medicinal Chemistry, Vol. 34, No. 3 (1991) pp. 992-998.		
OF	54.	International Search Report for analogous PCT Application No. PCT/US01/03385 dated June 11, 2001.		
OF	55.	ISHIHARA et al. "Scandium Trifluoromethanesulfonate as an Extremely Active Acylation Catalyst" J. Am. Chem. Soc., Vol. 117, No. 15 (1995) pp. 4413-4414.		
OF	56.	KINGSTON et al. "The Chemistry of Taxol, A Clinically Useful Anticancer Agent" Journal of Natural Products, Vol. 53, No. 1 (1990) pp. 1-12.		
OF	57.	KLEIN "Synthesis of 9-Dihydrotaxol: A Novel Bioactive Taxane" Tetrahedron Letters, Vol. 34, No. 13 (1993) pp. 2047-2050.		
OF	58.	LIANG et al. "Synthesis and Biological Evaluation of Paclitaxel Analogs Modified in Ring C" Tetrahedron Letters, Vol. 36, No. 17 (1995) pp. 2901-2904.		

Examiner Signature		Date Considered	12-03
--------------------	---	-----------------	-------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
<p style="text-align: center;">FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="text-align: center;">(use as many sheets as necessary)</p>				Application Number	10/606,027
				Filing Date	Jun 25, 2003
				Confirmation Number	To Be Assigned
				First Named Inventor	Robert A. Holton
				Group Art Unit	1625
				Examiner Name	Ba K. Trinh
Sheet	5	of	5	Attorney Docket No.	FSUM 10466.59

ST	59.	MELLADO et al. "Preparation and Biological Activity of Taxol Acetates" Biochemical and Biophysical Research Communications, Vol. 124, No. 2 (1984) pp. 329-336.	
ST	60.	OJIMA et al. "New Photoaffinity Analogs of Paclitaxel" Bioorganic & Medicinal Chemistry Letters, Vol. 9 (1999) pp. 1189-1194.	
ST	61.	PATEL "Tour De Paclitaxel: Biocatalysis for Semisynthesis" Annu. Rev. Microbiol. Vol. 52 (1998) pp. 361-395.	
ST	62.	SHI et al. "Studies on the Quantitative Structure-Activity Relationships of Paclitaxel Analogues" GAODENG, XUOXIAO, HUAXUE XUEBAO, Vol. 21, No. 3 (2000) pp. 401-406.	
ST	63.	STRAUBINGER et al. "Pharmacology and Antitumor Effect of Novel Paclitaxel Formulations" Chapter 8, Edited by G. Georg et al., Taxane Anticancer Agents, Basic Science and Current Status, ACS Symposium Series 583, 207th National Meeting of the American Chemical Society, San Diego, CA (1994) pp. 111-123.	
ST	64.	SUFFNESS "Chapter 32. Taxol: From Discovery to Therapeutic Use" Annual Reports in Medicinal Chemistry, Vol. 28 (1993) pp. 305-314.	
ST	65.	VYAS et al. "Phosphatase-Activated Prodrugs of Paclitaxel" Chapter 9, Edited by G. Georg et al., Taxane Anticancer Agents, Basic Science and Current Status, ACS Symposium Series 583, 207th National Meeting of the American Chemical Society, San Diego, CA (1994) pp. 124-137.	

Examiner Signature		Date Considered	12-03
--------------------	---	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.